A Weight Management Dietitian’s Thoughts on “Reta”

A Weight Management Dietitian's Thoughts on “Reta”

You’ve probably seen the headlines about “Reta” (retatrutide), the next-generation weight-loss injection making waves in RTÉ and BBC coverage, alongside worrying reports of a black-market trade in copycat versions. Clients have started asking us about it, so here’s where things stand, and what actually falls within our scope as dietitians working in weight management.

The basics

Retatrutide is a “triple agonist” injectable, still in clinical trials, that targets three metabolic pathways (GIP, GLP-1 and glucagon), rather than the one or two targeted by medications already available in Ireland, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). Trial data published in the New England Journal of Medicine showed weight loss of around 24% of body weight over 48 weeks at the highest dose, which is gaining a lot of attention (1). Beyond weight loss, research has also shown consistent improvements in markers of health, such as blood pressure and HbA1c (2), as well as promising reductions in liver fat (3). A 2025 study also found that retatrutide reduced appetite, hunger and the tendency to overeat, helping us better understand how treatment may change people’s relationship with food (4).

Important: Retatrutide is not currently available on prescription

Retatrutide is still being studied and has not yet been approved for use by any regulatory authority. This means that any products being sold online or through unofficial sources are unregulated and may not contain what they claim to. If you’re considering weight-loss medication, the safest place to start is with your GP or a qualified prescribing healthcare professionalю

Where a Dietitian Fits In

Where a Dietitian Fits In

Whatever medication someone is taking, Ozempic, Wegovy, Mounjaro or, in future, an approved version of retatrutide, the medication is only one part of the picture. These medications can significantly reduce appetite and food intake, but that does not automatically mean someone is meeting their nutritional needs. This is where a dietitian can help (5).

  • Protein: When weight is lost quickly, we want to protect muscle as much as possible. A protein target of around 1.2-1.5 g/kg per day, spread across the day, can help support muscle and physical function (6).
  • Nutrient density: People taking these medications may eat substantially less. This can increase the risk of functional malnutrition and nutrient deficiencies, including vitamin D, iron, B12, calcium and magnesium (7).
  • Hydration and side effects: Drinking enough is important, particularly when appetite and thirst are reduced. Around 2-4 litres of fluid per day may be appropriate depending on individual needs. Smaller meals and gradually increasing fibre can also help manage common side effects such as nausea and constipation (6).
  • Long-term habits: Many people stop these medications within the first year, often because of cost, side effects or problems accessing treatment (8). Building realistic eating habits alongside medication means people have support and practical skills that can continue if treatment changes or stops.

Ultimately, these medications can be powerful tools, but they are not a replacement for nutrition support. The latest guidance highlights the importance of dietitians working alongside prescribers and other healthcare professionals to help make these treatments as safe and effective as possible (9).

We’re here to help

Retatrutide may become an important option down the line, but for now, the safest, evidence-based route is through your GP and an approved medication, if that’s the right path for you.
If you’re taking Ozempic, Wegovy or Mounjaro and want support finding your rhythm with food, we’re here for that. With the right support, it can feel much more manageable and far less overwhelming.
Our team of experienced Registered Dietitians are here to help. Book a consultation with Gillian McConnell, founder and CEO of Inside Out Nutrition, or Ellen Curran, our weight management dietitian, for tailored advice and support that is flexible, balanced and grounded in real life.
Take the first step towards feeling your best: schedule your appointment today.
Sources of Information

  1. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. New England Journal of Medicine. 2023 Aug 10;389(6):514–26.
  2. Pasqualotto E, Ferreira RO, Chavez MP, Hohl A, Ronsoni MF, Pasqualotto T, de Moraes FC, Hespanhol L, Watanabe JM, Lütkemeyer C, van de Sande-Lee S. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024 Dec 1;24:100321.
  3. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024 Jul;30(7):2037–48.
  4. Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, Obesity and Metabolism. 2025 Dec;27(12):6988–98.
  5. Gigliotti L, Warshaw H, Evert A, Dawkins C, Schwartz J, Susie C, Kushner R, Subramanian S, Handu D, Rozga M. Incretin-based therapies and lifestyle interventions: the evolving role of registered dietitian nutritionists in obesity care. Journal of the Academy of Nutrition and Dietetics. 2025 Mar 1;125(3):408–21.
  6. Sievenpiper JL, Ard J, Blüher M, Chen W, Dixon JB, Fitch A, Gigliotti L, Khunti K, Lecube A, Lean ME, Mittendorfer B. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars. 2025 Nov 11:100228.
  7. Alexa RE, Haliga RE, Morărașu BC, Ceasovschih A, Sîrbu O, Asaftei A, Șorodoc V, Șorodoc L. The nutritional paradox of obesity: Mechanisms and clinical implications of micronutrient deficiencies. Medical Sciences. 2026 Mar 24;14(2):160.
  8. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025 Aug;33(8):1475–503.
  9. Dobbie LJ, Tolvanen L, Alves D, Baker JL, Bez NS, Birney S, Bogl LH, Brown A, Bullo M, Clare K, Duncan EL. Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement. The Lancet Diabetes & Endocrinology. 2026 Jul 8.
0